Cullinan Therapeutics, Inc. Common Stock

CGEM · Biotechnology · $1.4B
Powering up
CGEM
$21.08
▼ −1.31%
09/18 O 21.38 H 21.45 L 20.63 C 21.08 ▼ −1.31%
Vol 3.3M RS 97
RS rating97
Now vs pivot (%)−9.10%
Tightening (ATR ratio)0.84×
Volume dry-up0.48×
Up/down volume, net-0.08
From 52-week high9%
forming
Previous breakout still open ▲ +7.39% in Aug
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 3.4 weeks and fell 20% from its ceiling at its deepest. The pivot is $23.19, and the stock closed 9.1% below it. Its relative strength rating is 97.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap
  1. Earningstentativein 57d
    Quarterly earnings
    Nov 14, 2026
Flagged by the market sweep

Nothing flagged for this company on the last market sweep.

In the news
Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Cullinan Therapeutics, Inc. Common Stock (CGEM) — The Tape